Car T cells are one of the most promising fields for cancer therapies. There are dozens of emerging partnerships out there between big Pharma and specialists in the area. The use of autologous T-cells (a patient's own) has various limitations. The potential of CAR T cells in cancer immunotherapy is huge.

Advances in Allogeneic or “off-the-shelf,” CAR T cells give scale, quality and consistency benefits. Fate Therapeutics (FATE) is one of the mkt leaders that entered into a partnership with J&J last year.
Tap to copy the Short Url to this post: 
All Business News on a Single Page. Join for Free →